Navigation Links
ARIUS presents new findings for anti-cancer antibody programs at AACR
Date:4/15/2008

ng Trop-2.

A humanized version of this antibody has greater higher affinity than the murine version and will be used in a pre-clinical toxicology study. A cell line has been developed for the Trop-2 targeting antibody and it is currently in manufacturing to generate material for Phase I clinical studies.

CD59 Complement Inhibitor Program

A monoclonal antibody targeting CD59 (AR36A36.11.1), enhances complement activity and exhibits potent in vivo efficacy in multiple human cancer models. Abstract Number 3995. Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008, 8:00 AM

ARIUS has expanded its expression profiling and has characterized the affinity for its CD59 targeting antibody, AR36A36.11.1. This antibody has demonstrated significant in vivo anti-tumor activity towards a broad range of high incidence cancers and is highly potent at low dose concentrations in tumor xenografts, comparing favorably to standard of care in breast and prostate cancer.

The effectiveness of this very potent antibody may be attributed to its ability to block CD59 function, representing a novel approach to cancer treatment. Currently, there are no other reported naked therapeutic antibodies targeting CD59 in clinical development.

A humanized version of ARIUS' CD59 targeting antibody demonstrated equivalent affinity and potency to the murine version, and a CHO cell line producing humanized AR36A36.11.1 has been generated to manufacture material for future clinical studies.

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is develop
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ARIUS announces first quarter fiscal 2008 financial results
2. ARIUS 2008 Annual and Special Meeting of Shareholders
3. ARIUS recognized for entrepreneurial excellence
4. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
5. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
6. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
7. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
8. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
9. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
10. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
11. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of strategic ... business, and media events in the United States ... associate Virginia Cox , JD, is returning to the firm,s ... Cox re-joins 3D after more than two years of service ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... 14, 2014 Global Record Systems, ... information technology solutions for patients, physicians, the biopharmaceutical ... announced today the signing of a three-year Research ... Drug Administration (FDA). This initiative is designed ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... SHANGHAI, June 29 /PRNewswire-Asia/ -- Sundia MediTech Company, ... Shanghai,China announced today that Dr. Tong Xu has been ... Prior to joining Sundia, Dr. Xu worked ... in San Diego, USA for 12 years. At ...
... Mylan Inc. (Nasdaq: MYL ) today ... with Biocon Limited, a publicly traded company on ... on the development, manufacturing, supply and commercialization of ... global marketplace. Through this partnership, Mylan and Biocon ...
... UPPSALA, Sweden, June 29 , ... Will Fund Gyros to Profitability , ... development, announces that it has raised SEK 80 million,(approximately euro ... Company,s leading shareholder. The new funds will enable Gyros to ...
Cached Biology Technology:Sundia MediTech Appoints Dr. Tong Xu as VP of Process Chemistry 2Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market 2Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market 3Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market 4Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 2Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 3Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 4
(Date:7/9/2014)... Jena (Germany) They are amongst the most numerous inhabitants ... Emiliania huxleyi . Not visible to the naked eye, ... square kilometer sized patches, they are even visible on ... is responsible for approximately half of the global ... Friedrich Schiller University Jena (Germany). In the process the ...
(Date:7/9/2014)... they are used in the right ways. ... Hospital and coauthors analyzed six use cases with ... decompensation (when a patient,s condition worsens); adverse events; ... organ systems. They suspect that cost-savings benefits will ... all six scenarios will be significant. The authors ...
(Date:7/8/2014)... LAKE CITY, July 9, 2014 Collectors found the first ... in west Texas. Then, for two decades, the 14-inch-tall plant ... a third. , Now after a long search turned ... Utah botanist and her colleagues identified the spiny plant as ... heart" in Latin because it was found in Valentine, Texas, ...
Breaking Biology News(10 mins):Short circuit in the food web 2The impact of big data on health care: Health Affairs' July issue 2New plant species from the heart of Texas 2New plant species from the heart of Texas 3New plant species from the heart of Texas 4New plant species from the heart of Texas 5
... Space is not a fun place to get a stomach ... Utah chemists developed a two-minute water quality monitoring method that ... Station. "Now they bring water back on the space ... there is a big delay. You,d like to be able ...
... difference can a tenth of a nanometer make? When it ... resolution of that miniscule amount can mean the difference between ... Case in point: New, improved-resolution views of a zinc transporter ... Laboratory provide not just a structure but also a suggested ...
... stamp that can sniff out poisonous gases or deadly toxins ... 13 issue of the journal Nature Chemistry , Kenneth ... developed an artificial nose for the general detection of toxic ... and works by visualizing odors. This sensor array could ...
Cached Biology News:Water quality in orbit 2Water quality in orbit 3Water quality in orbit 4High-res view of zinc transport protein 2High-res view of zinc transport protein 3Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3
...
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
... The NEW HandyStep electronic from BRAND ... pipetting. It is the only electronic, ... standard syringe tips, including BRAND PD-Tip ... Plus, Fisherbrand Dispenser Tips,and VWRbrand Combi-Syringes. ...
Biology Products: